一个患有多系统性缩-帕金森型的患者呈现出渐进式微图
Halil Onder1, Beyza Nur Cetin1, Selcuk Comoglu1
1Neurology Clinic, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Türkiye.
Asian journal of neurosurgery
|July 8, 2024
概括
多个系统缩 (MSA) 可以导致渐进式微写 (PM),这是一个与帕金森病不同的写作困难. 需要进一步的研究来了解这种运动障碍的表现及其神经基础.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
- 神经退行性疾病 神经退行性疾病
背景情况:
- 渐进式微写 (Progressive micrographia,简称PM) 是一种书写障碍,其特点是尺寸和速度的减少.
- 多系统缩 (MSA) 是一种进展性神经退行性疾病,影响多个系统.
- 区分MSA亚型及其特定表现对于准确的诊断和管理至关重要.
研究的目的:
- 在被诊断为多系统缩 (MSA) 的患者中报告进展性微图 (PM) 的病例.
- 突出PM作为特定MSA亚型中的潜在表现.
- 强调PM在MSA和帕金森病中的临床和病理生理差异.
主要方法:
- 一个57岁的男性患者的案例介绍,他有3年的书写困难和右手缓慢的病史.
- 临床评估和实验室工作以确立诊断.
- 考虑到帕金森病和其他运动障碍的差异诊断.
主要成果:
- 患者被诊断为多重系统缩 (MSA).
- 渐进微图 (PM) 被确定为一个关键症状.
- 在这种MSA病例中,PM的临床表现与典型的帕金森病表现不同.
结论:
- 渐进性微图 (PM) 可能是多重系统缩 (MSA) 的一个有趣的表现.
- 这一案例强调了与帕金森病相比,MSA的独特临床和病理生理特征.
- 需要进一步的研究,以阐明PM在MSA中的重要性和神经机制.
更多相关视频
10:28Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
15.2K
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.8K
相关概念视频
Parkinson's Disease: Overview
522
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
522
Parkinson's Disease: Treatment
251
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
251
Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
